NovoCure Limited

NasdaqGS NVCR

NovoCure Limited Total Non-Current Liabilities for the year ending December 31, 2023: USD 604.52 M

NovoCure Limited Total Non-Current Liabilities is USD 604.52 M for the year ending December 31, 2023, a 2.17% change year over year. Total non-current liabilities are the sum of long-term debt and other non-current liabilities.

NovoCure Limited Total Non-Current Liabilities for the year ending December 31, 2022 was USD 591.70 M, a 0.90% change year over year.
NovoCure Limited Total Non-Current Liabilities for the year ending December 31, 2021 was USD 586.40 M, a 26.97% change year over year.
NovoCure Limited Total Non-Current Liabilities for the year ending December 31, 2020 was USD 461.85 M, a 163.39% change year over year.
NovoCure Limited Total Non-Current Liabilities for the year ending December 31, 2019 was USD 175.35 M, a 7.59% change year over year.

Key data

Date	Total Non-Current Liabilities	Shareholders' Equity	Other Liabilities	Total Liabilities

NasdaqGS: NVCR

NovoCure Limited

CEO	Mr. Asaf Danziger
IPO Date	Oct. 1, 2015
Location	Jersey
Headquarters	No. 4 The Forum
Employees	1,453
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.

Key trends

Past 5 years